EPZ019997 is primarily utilized in biomedical research, particularly in the study of epigenetics and cancer. It functions as a potent and selective inhibitor of the protein arginine methyltransferase 5 (PRMT5), an enzyme involved in the regulation of gene expression. By inhibiting PRMT5, EPZ019997 helps researchers investigate the role of this enzyme in tumor growth and progression, offering insights into potential therapeutic strategies for cancers driven by PRMT5 dysregulation. Its application extends to preclinical studies where it is used to evaluate the efficacy of PRMT5 inhibition in reducing cancer cell proliferation and survival. Additionally, EPZ019997 serves as a valuable tool in understanding the broader implications of epigenetic modifications in disease mechanisms.